There are always islands of opportunities in every difficulty!
2020 will provide TOPADUR with even more attractive investment opportunties due to the fact that we are in transition from a pre-clinical to a clinical stage company and as a second major milestone will finalize the very important toxicology studies by year-end 2019. The start of our first clinical study in the spring of 2020 remains our top priority. Another highlight in 2020 is the expansion of our medical compound portfolio to various interesting new R&D product candidates (please see current business presentation below).
From your point of view as an Investor our sector will most certainly provide new opportunities and an ideal occasion for an in depth market and investment reflection. We hope to draw your attention with regard to the current investment environment in general and particularly in the biotechnology sector in Switzerland.
SWISS BIOTECH SECTOR REVIEW 2019IR_SWISS BIOTECH REVIEW 2019_V04_EN
So, why not considering an alternative investment in TOPADUR in the near future?
CURRENT TOPADUR BUSINESS BROCHURE 2019Topadur Pharma AG - overview investment case_Web-DEC2019_Final
WHY SHOULD YOU INVEST IN TOPADUR ?
What exactly are the key arguments to be raised to actually invest in TOPADUR and what makes us an added value provider and important asset for your private equity portfolio ?
Find out more
The interested investors will obtain more information via our Investors Relations Contact below:
TOPADUR PHARMA AG
Markus Ducrey TEP SACTM
Finance | Strategy | IT
T: 41 44 755 44 61